Join a Trial
As one of its primary objectives, our dynamic research program is working to identify which patients stand to benefit the most from proton therapy. Many of our radiation oncologists are leading large national clinical trials that are available to our patients. Ninety-seven percent (97%) of our patients are enrolled in one of these studies or in one of the many other clinical trials available at our center.
Patients interested in participating in any of these clinical trials should speak to their radiation oncologist about eligibility.
Current Clinical Trials
Learn about the various clinical trials that are currently enrolling New York Proton Center patients.
Breast Cancer
PCG BRE 007-12 Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer: NCT01766297
PCG BRE 009-23 Phase III Randomized Trial of Conventionally Fractionated vs. Hypofractionated COMprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning PROton Therapy (COMPRO): NCT05856773
CNS Cancer
NRG-BN014 A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation versus Involved Field Radiotherapy for Patients with Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal Metastasis: NCT06500481
Gastrointestinal Cancers
NRG GI006 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer: NCT03801876
Head and Neck Cancers
ECOG-ACRIN EA3191 A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High-Risk Features: NCT04671667
NRG-HN014 Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment Versus Standard of Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma NCT06568172
MSK 22-215 Major Radiation Dose De-Escalation Concurrent with Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma: NCT05491512
MSK 22-227 A Pilot Study of Radiation De-Escalation for p16 Negative Oropharyngeal Cancer and p16 Negative or Positive Laryngeal and Hypopharyngeal Cancers: NCT05544136
MSK 25-040 Major Radiation Dose De-Escalation Concurrent with Chemotherapy for Advanced Stage Human Papilloma Virus Associated Oropharyngeal Carcinoma: NCT06984861
MSK 24-200 Phase III randomized and double-blinded trial of de-escalated radiation in FMISO PET-selected good risk versus standard of care radiation in unselected HPV positive oropharyngeal cancer NCT06563479
Pediatric Cancers
Proton and Photon Consortium Registry (PPCR) A Multi Center Registry of Pediatric Patients Treated with Radiation Therapy: NCT01696721
COG ACNS2021 A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor: NCT04684368
COG-ARST2032 A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma: NCT05304585
COG-AHOD2131 A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma: NCT05675410
COG-ACNS2321 A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas: NCT06368817
COG-ACNS1821 A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG): NCT05099003
COG-ACNS2031 A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features: NCT05382338
COG-ARAR2331 Prospective Treatment of Types I, II, and III Pleuropulmonary Blastoma (PPB): NCT06647953
COG-ARAR2221 A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC) NCT06064097
COG-AOST2032 A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotocix Chemotherapy for Newly Diagnosed Osteosarcoma NCT05691478
COG-ANBL2131 A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma NCT06172296
COG-ANBL1531 A Phase 3 Study of I-Metaidobenzylguanidine (I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma NCT03126916
COG-AREN2231 Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) NCT06401330
MSK 24-144 N10: Reduced Therapy for High Risk Neuroblastoma: NCT06528496
Recurrent Cancer
NYPC 2019-002 Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors: NCT05313191
Thoracic Cancers
NRG LU008 Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer: NCT05624996
NYPC 2021-030 Patient Generated Health Data Collection During Chemoradiotherapy for Lung Cancer: A Pilot Study: NCT06342284
MSK 22-098 Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Patients With Pleural Metastases From Thymic Malignancies: NCT05354570
MSK 25-310 A Phase I/II Study of BIO 300 to Reduce the Toxicity of Thoracic Radiotherapy for Patients with Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease (BREATHE) NCT07323732
All Cancer Types
PCG REG001-09 Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy: NCT01255748
Proton Therapy Effectiveness
Clinical data validates proton therapy as an effective cancer treatment that is neither experimental nor investigative. We can share our research validating proton therapy as an effective cancer treatment with your insurance provider.
